Sequential therapy with daunorubicin and L-asparaginase in relapses of acute lymphoblastic leukemia in children.
13 children affected by acute lymphoblastic leukemia in advanced stage of illness received a sequential therapy with daunorubicin and L-asparaginase. During daunorubicin therapy a significant decrease of bone hypercellularity as well as circulating cells occurred, a further cycle with a scarcely myelotoxic drug, L-asparaginase, was administered: a 10/13 (76.9%) remission of the disease was then achieved. This therapeutic trial was well accepted and could be more extensively used in the patients in relapse. A remission lasting between 4 and 28 weeks was observed.
D001215:Asparaginase / Q000009:adverse effects / Q000627:therapeutic use*; D001856:Bone Marrow Examination; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003630:Daunorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D012008:Recurrence; D012075:Remission, Spontaneous
D001215:Asparaginase; D003630:Daunorubicin